Viva Biotech is an integrated drug discovery platform that specializes in providing comprehensive drug discovery services and Contract Development and Manufacturing Organization (CDMO) services. The company operates a unique investment and incubation arm, Viva BioInnovator, which supports the creation and development of biotech startups by offering operational support, CRO drug discovery services, and financial backing. Founded in 2014, Viva Biotech recognized a significant gap in funding for innovative biotech ideas lacking sufficient data. Its "equity for service" model enables startups to transform their concepts into clinical programs. With a global reach, Viva Biotech has invested in over 30 companies, predominantly based in the United States, while remaining open to proposals from around the world. The company has offices in Shanghai and Boston, with personnel located in California, and continues to pursue new investment opportunities to foster innovation in the biotech sector.
Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. It is committed to solving the problem of drug metabolism and the delivery of cytogenic drugs.
TechnoDerma Medicines
Series B in 2024
TechnoDerma Medicines is a private clinical-stage biopharmaceutical company dedicated to developing innovative therapies for various skin diseases. Its research and development efforts focus on small molecular drugs aimed at treating conditions such as androgenetic alopecia, atopic dermatitis, psoriasis, lupus erythematosus, and scars. The company's goal is to provide patients with safe and effective treatment options, addressing unmet medical needs in the dermatological field.
Anji Pharmaceuticals
Venture Round in 2024
Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.
Full Circles Therapeutics
Venture Round in 2024
Full Circles Therapeutics is a biotechnology company specializing in the development of genome surgery platforms aimed at treating genetic diseases and cancer. The company focuses on creating a viral-free method for genome surgery, which allows for the insertion of diverse genetic sequences at specific locations within the human genome of disease-relevant cells. This innovative approach is designed to facilitate the treatment of severe genetic conditions and various forms of cancer, positioning Full Circles Therapeutics at the forefront of curative genomic medicine.
Exarta Therapeutics
Venture Round in 2024
Exarta Therapeutics is a pre-clinical biotechnology company focused on developing innovative drugs aimed at treating cancer tumors. Currently operating in stealth mode, the company is engaged in early-stage research and development to create effective therapeutic solutions for cancer patients. With a commitment to advancing cancer treatment, Exarta Therapeutics seeks to contribute to the ongoing efforts in the fight against this disease.
Calira Therapeutics
Venture Round in 2024
Calira Therapeutics is a biotech company focusing on allosteric inhibitors of CaMK2 for the treatment of diabetes and heart failure.
DEKA Biosciences
Series B in 2023
DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.
i2O Therapeutics
Series A in 2023
i2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, it leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2o is focused on creating the next generation of oral peptide and protein-based therapies. The company was founded in 2019 and based in Saratoga, California.
Reglagene
Venture Round in 2023
Reglagene LLC is a therapeutics company based in Tucson, Arizona, founded in 2016. The company specializes in gene expression services and research and development, utilizing DNA quadraplex master switch technology to create precise on and off switches for controlling gene expression. Reglagene focuses on developing therapies for a range of diseases, including cancer, neurodegeneration, and metabolic disorders. A key aspect of its work involves transforming tubulin therapy for brain diseases, with an emphasis on creating effective treatments that can penetrate the blood-brain barrier. The company's portfolio includes innovative therapies aimed at addressing brain inflammation and ocular neovascularization, with the goal of combating diseases linked to changes in gene processing rates.
WM Therapeutics
Venture Round in 2023
WM Therapeutics is a drug discovery company that discovers and develops novel cancer therapies that limit tumor-autonomous growth and stimulate the immune system to attack the tumor.
f5 Therapeutics Incorporated
Venture Round in 2023
F5 Therapeutics focuses on precision-based protein degradation to eliminate disease-causing proteins that are resistant to conventional treatment methods. The company specializes in developing targeted protein degraders, including small molecule drugs and molecular glues, aimed at various conditions such as oncology, immuno-oncology, autoimmune diseases, and fibrosis. By employing proprietary techniques for discovering novel targets for protein degradation, F5 Therapeutics enables researchers to create targeted therapies with unique degradation profiles. This approach not only facilitates the understanding of critical signaling pathways in stem cells during embryonic development but also supports homeostasis and regeneration in adult organisms.
NAKI Therapeutics
Venture Round in 2023
NAKI Therapeutics is a biopharmaceutical company established in 2020 and based in Summit, New Jersey, focusing on the development of innovative immunotherapies for cancer treatment. The company specializes in Chimeric Antigen Receptor (CAR)-Natural Killer (NK) cell therapies, which are designed to effectively and safely eliminate cancer cells. NAKI Therapeutics re-engineers NK cells to specifically target the CD147 surface marker found on cancer cells, enhancing the potential for more effective treatment outcomes compared to traditional therapies. Through its research-driven approach, NAKI Therapeutics aims to advance the field of cancer immunotherapy and improve patient care.
Domain Therapeutics
Series A in 2022
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.
GT Apeiron Therapeutics
Series A in 2022
GT Apeiron Therapeutics is a developer of innovative drugs utilizing artificial intelligence technology. The company develops breakthrough investigational medicines by harnessing the power of artificial intelligence, aiming to drastically increase efficiency throughout the drug discovery process.
ArrePath
Seed Round in 2022
ArrePath is a company focused on discovering anti-infective drugs to tackle the global issue of drug-resistant infections. It operates a drug discovery platform that aims to develop therapies specifically targeting antimicrobial resistance. The platform is designed to create new medicines that address multiple targets within disease pathways, which may enhance treatment efficacy while minimizing risks during the discovery and development phases. This approach supports healthcare professionals in treating chronic infections and improving patient recovery times.
HAYA Therapeutics
Seed Round in 2022
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.
XLement
Venture Round in 2022
XLement provides all-around intelligent medical testing products and programs for medical institutions and consumers.
Bichen Pharmaceutical
Series B in 2022
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.
Amberstone Biosciences
Series A in 2022
Amberstone Biosciences specializes in the discovery of novel immunotherapies aimed at addressing unmet medical needs through advanced technologies and strategic collaborations. The company focuses on challenging therapeutic targets that require unique mechanisms of action, which traditional methods struggle to tackle. Amberstone employs a microfluidics-powered drug discovery platform, known as AmberFlow, to analyze single-cell functions within a customizable microenvironment. This innovative approach allows for a more precise understanding of immune responses, enabling the development of transformative therapeutic antibodies. The team's expertise in immuno-oncology and single-cell assay biology further enhances their capacity to create effective treatments, ultimately improving patient outcomes.
Focus-X Therapeutics
Venture Round in 2022
Focus-X Therapeutics is a preclinical-stage biotechnology company that specializes in the development of radiopharmaceuticals for cancer treatment. The company aims to address unmet needs in cancer diagnosis and therapy by employing a theragnostic approach, particularly targeting solid tumors with low five-year survival rates. Focus-X Therapeutics is advancing its proprietary radioligand therapy, which utilizes alpha and beta emitters to precisely disrupt cancer cell DNA. By optimizing peptide ligand vectors, the company seeks to create innovative theranostic agents that offer medical practitioners new mechanisms for treating cancer effectively.
Flash Therapeutics
Venture Round in 2022
Flash Therapeutics develops drug candidates to selectively target leukemic stem cells and prevent AML relapse.
Tatara Therapeutics
Venture Round in 2022
Tatara Therapeutics is a pre-clinical stage company dedicated to developing precision medicine for cancer treatment by targeting metabolic changes in iron homeostasis associated with mutant RAS and other oncogenes. The company utilizes its proprietary iron-activated drug conjugate (FeADCTM) technology to create a pipeline of in vivo active leads aimed at enhancing the detection and targeting of cancer-causing tumors. By exploiting mechanisms such as ferroptosis and ferrous addictions, Tatara Therapeutics seeks to improve therapeutic outcomes in oncology, providing innovative solutions for patients with cancer.
Ornovi
Venture Round in 2022
Ornovi is a pre-clinical stage therapeutics company developing treatments for inflammatory and autoimmune diseases. The company focuses on a selective JAK3/ITK dual inhibitor for the treatment of alopecia areata, vitiligo, and other inflammatory and autoimmune diseases.
QureBio
Series B in 2021
QureBio focuses on the research and development of innovative macromolecular biopharmaceuticals. Its goal is to develop new therapeutic drugs for the treatment of refractory cancer, autoimmune diseases, and metabolic diseases in China and the world to benefit patients. QureBio has multiple technology platforms for antibody drug development including phage display technology platforms and hybridoma antibodies technology platform and monoclonal antibody platform. The company was founded in 2017 and is based in Pudong District, Shanghai.
Fuse Biotherapeutics
Seed Round in 2021
Fuse Biotherapeutics is a biotechnology company focused on developing innovative immune-modulating therapeutics for cancer patients. Established in 2021 and based in Los Angeles, the company employs a rational approach to its therapeutic development, integrating multiple steps of the immune response. This approach aims to harness potent immune responses to target cancer effectively while preserving the natural mechanisms that protect healthy tissues. By prioritizing safety alongside efficacy, Fuse Biotherapeutics seeks to create new treatment options that offer advantages over existing therapies in the cancer treatment landscape.
DEKA Biosciences
Series A in 2021
DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.
Nerio Therapeutics
Venture Round in 2021
Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, CA, USA.
IpiNovyx Bio
Seed Round in 2021
IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.
Karma Biotechnologies
Seed Round in 2021
Karma Biotechnologies, Inc. is a Los Angeles-based startup focused on developing therapies for autoimmune diseases, allergies, and food sensitivities. Founded in 2019, the company offers Xavines, a precision immunotherapy platform designed to address the critical need for antigen-specific therapies that target only the rogue immune cells responsible for these conditions. Unlike traditional treatments that rely on general immune suppression, Karma Biotechnologies aims to create tolerogenic immunotherapies that promote antigen-specific immune tolerance in vivo. By leveraging its expertise in immunology and lipid nanoparticle engineering, the company seeks to provide innovative solutions that enhance the treatment landscape for autoimmune diseases and related disorders.
Evecxia Therapeutics
Venture Round in 2021
Evecxia Therapeutics is a pharmaceutical company founded in 2013 and headquartered in Raleigh, North Carolina. The company focuses on developing drugs to address disabling neuropsychiatric conditions, particularly depression, which often remain inadequately treated by existing therapies. Evecxia is working on its lead product, EVX-101, which aims to enhance serotonin synthesis in the brain. By sustaining plasma levels of 5-HTP, the company seeks to amplify serotonin production, offering potential therapeutic benefits for patients facing conditions like depression and acute suicidal ideation crises. Evecxia's approach emphasizes risk-mitigated pharmacology, providing healthcare professionals with new options for antidepressant treatment.
Aleta Biotherapeutics
Series A in 2021
Aleta Biotherapeutics is an immuno-oncology company established in 2015 and headquartered in Natick, Massachusetts. The company specializes in the development of cellular therapeutics aimed at addressing a wide range of cancer indications, particularly focusing on challenging and intractable solid tumors. By transforming cellular therapeutics, Aleta Biotherapeutics enables healthcare professionals to target various tumor types more effectively, thus enhancing treatment options for patients facing difficult cancer cases.
Grove Biopharma
Pre Seed Round in 2021
Grove Biopharma is a biotechnology company dedicated to addressing unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. It specializes in the discovery and development of a new class of protein-like polymers, utilizing artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics. The company also provides materials science solutions to tackle challenges associated with peptide therapeutics, thereby facilitating researchers' access to innovative drugs in critical areas of healthcare.
Telo Therapeutics
Venture Round in 2021
Telo Therapeutics is a biotechnology company focused on developing innovative treatments to combat cancer by reversing the immortality of cancer cells. The company's approach centers on inhibiting telomerase, an enzyme that cancer cells utilize during their immortalization process. By targeting this enzyme, Telo Therapeutics aims to preserve healthy cells while effectively treating cancer, thereby enhancing the survival and quality of life for patients who have exhausted other treatment options. Through its precision medicine platform, the company seeks to improve treatment outcomes and offer new hope to those affected by cancer.
HAYA Therapeutics
Seed Round in 2021
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.
HAYA Therapeutics
Seed Round in 2021
HAYA Therapeutics is focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company's innovative approach involves targeting a heart-specific regulator of fibrosis, specifically a long noncoding RNA, to block myocardial fibrosis. This biopharmaceutical therapy aims to improve the efficacy and safety of treatment for heart-related illnesses and other serious health conditions associated with aging, including cancer. By concentrating on tissue and cell-selective genomic medicines, HAYA Therapeutics seeks to provide more precise and effective therapeutic options for patients suffering from these conditions.
Cybrexa Therapeutics
Series B in 2021
Cybrexa, Inc. is focused on developing innovative DNA repair inhibitors aimed at enhancing cancer therapeutics through the use of peptide-based technology that directly targets the tumor microenvironment. Established in 2016 and based in New Haven, Connecticut, the company leverages a unique tumor-localizing peptide technology developed at Yale University. This approach aims to revolutionize drug delivery by improving the therapeutic index, allowing for safer administration of higher doses of chemotherapy and radiotherapy. Cybrexa's pipeline includes a collection of small molecule inhibitors that can be combined with existing anticancer agents, thereby expanding treatment options for patients and addressing significant unmet medical needs in oncology. Through its research, Cybrexa seeks to improve patient outcomes and redefine the landscape of cancer treatment.
DTx Pharma
Series B in 2021
DTx Pharma, LLC is a biotechnology company focused on developing and commercializing fatty acid-conjugated peptide therapeutics for patients with rare and chronic diseases. The company specializes in RNA-based therapeutics, utilizing a delivery technology platform that enhances the distribution of nucleic acid drugs to various tissues and organ systems beyond the liver. This innovative approach addresses limitations associated with previous-generation RNA delivery methods, such as poor pharmacokinetics and inadequate cellular uptake. DTx Pharma's products target conditions including retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system disorders. Founded in 2017 and based in San Diego, California, DTx Pharma aims to provide personalized treatment options across multiple therapeutic areas.
AmacaThera
Series A in 2021
AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.
Iterion Therapeutics
Series B in 2021
Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing targeted therapeutics for cancer treatment. Founded in 2010, the company specializes in innovative cancer therapies, with its leading product, Tegavivint, being a selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a significant role in processes such as cell proliferation and immune evasion. Tegavivint has shown pre-clinical efficacy in various cancer models, including desmoid tumors, acute myeloid leukemia, osteosarcoma, and several solid tumors. Iterion is currently conducting a Phase I clinical study for Tegavivint in patients with desmoid tumors across multiple clinical sites in the United States and Canada, aiming to provide effective treatment options for patients with challenging cancers.
Seraxis
Series C in 2021
Seraxis is a biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell and encapsulation technologies aimed at creating a practical cell therapy for insulin-dependent diabetes. Their primary objective is to provide a long-term cure for diabetic patients that eliminates the need for immunosuppression, thereby improving the management of glucose levels through the production of insulin. Seraxis is structured to expedite the development of this therapy while maximizing value for its shareholders.
Blue Oak Pharmaceuticals
Series A in 2021
Blue Oak Pharmaceuticals is a pharmaceutical company focused on developing innovative treatments for brain disorders. Founded in 2016 and based in Concord, Massachusetts, the company employs a unique drug discovery paradigm that combines custom-designed chemotypes with advanced technologies such as behavioral profiling, synthetic chemistry, and brain imaging. By integrating in vivo phenotypic assays and high-content data analysis, Blue Oak aims to identify first-in-class drugs that target the neurobiology of brain disorders. The company's team of experts collaborates globally with established partners to enhance productivity and drive clinical candidates into early-phase proof-of-concept studies, utilizing translational medicine biomarkers to assess brain circuit activity.
Basking Biosciences
Seed Round in 2020
Basking Biosciences is a startup focused on developing a reversible thrombolytic therapy aimed at restoring blood flow to the brain during ischemic strokes, thereby preventing hemorrhage and minimizing long-term damage. The company’s innovative approach involves a paired therapy that combines an active agent targeting a crucial component of clot stability with a designed reversal agent. This reversal agent can be administered if bleeding occurs, effectively neutralizing the active compound and restoring the blood's normal clotting ability. By enabling healthcare professionals to treat acute ischemic stroke effectively, Basking Biosciences aims to improve patient outcomes in critical medical situations.
Phenomic AI
Seed Round in 2020
Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, founded in 2017. The company specializes in developing artificial intelligence solutions to enhance drug discovery and the creation of therapies for cancer. Its innovative platform utilizes AI, computer vision, and high-content screening to analyze phenotypes in complex disease models, such as high-content co-culture and three-dimensional assays. By focusing on the tumor stroma, Phenomic AI aims to optimize the discovery and development of new medicines, streamlining the process for pharmaceutical companies to identify potential drug candidates more effectively.
Sisu Pharma
Seed Round in 2020
Sisu Pharma focuses on creating targeted medications for patients suffering from therapy-resistant prostate cancer, which is the second most prevalent cancer among men globally. Despite the availability of various treatments, there is currently no cure, and patients often develop resistance over time, leading to severe health consequences. The company utilizes proprietary technology to specifically target Heat Shock Factor 1, a transcription factor essential for the survival and progression of advanced prostate cancer. This innovative approach not only aims to provide effective treatment options for patients who have exhausted other therapies but also opens avenues for developing new therapies for neurodegenerative diseases and infections.
Elgia Therapeutics
Seed Round in 2020
Elgia Therapeutics is a biotechnology company focused on developing innovative treatments for chronic inflammatory and fibrotic diseases. The company employs novel approaches in drug discovery, utilizing high-throughput chemical screening and structure-based design to identify and develop small molecule inhibitors targeting specific protein pathways. By understanding the role of metabolic stress in driving inflammation and fibrosis, Elgia Therapeutics aims to create effective therapies for patients suffering from debilitating chronic conditions. Its commitment to advancing healthcare through the development of these targeted treatments positions it as a significant player in the pharmaceutical and therapeutic landscape.
Antag Therapeutics
Venture Round in 2020
Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.
BioCasting Pharma
Venture Round in 2020
BioCasting Pharma is a clinical research company that provides humanized 3D disease model solutions based on microphysiological systems (MPS) for drug development institutions. It can currently provide system solutions for areas and products that are severely lacking preclinical evaluation tools, including infection/metabolism, tumor vascularization, gene and cell therapy, bispecific antibodies, and ADC.
Synthis Therapeutics
Venture Round in 2020
Synthis Therapeutics is an early-stage biotechnology company focused on developing innovative immuno-oncology therapeutics aimed at enhancing patient care and outcomes in cancer treatment. The company’s therapeutic platform targets the TGF-β pathway, known for its immunosuppressive effects in nearly all cancers. By selectively inhibiting this pathway, Synthis aims to rescue immune function, enabling the body’s immune system to effectively combat metastatic cancer. This approach seeks to improve the safety and efficacy of cancer therapies, ultimately enhancing patient survival and quality of life.
Saverna Therapeutics
Venture Round in 2020
Saverna Therapeutics AG is a Swiss biotechnology company established in 2017, located in Allschwil. The company specializes in drug discovery, utilizing a platform that integrates fragment-based screening, nuclear magnetic resonance spectroscopy, and machine learning. This innovative approach is aimed at developing small molecule drugs that selectively target specific microRNAs (miRNAs), with a focus on addressing diseases such as inflammation, cancer, and infections.
Bright Angel Therapeutics
Seed Round in 2019
Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.
AmacaThera
Seed Round in 2019
AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.
Argonaut Genomics
Venture Round in 2019
Argonaut Genomics is an early-stage biotech company that focuses on developing novel cancer antigens in solid tumors for therapeutic cancer vaccines and cell therapies.
Forkhead BioTherapeutics
Seed Round in 2019
Forkhead BioTherapeutics Inc is focused on developing innovative oral therapies for insulin-dependent diabetes. Based in New York, the company has created Foxin, an oral agent designed to target and delete the FOXO1 protein, which plays a crucial role in regulating insulin production and glucose metabolism. Founded in 2017, Forkhead Bio aims to harness the natural processes of cell conversion and regeneration to create transformative treatments that enhance the quality of life for patients with diabetes.
QurAlis
Seed Round in 2018
QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.
Riparian Pharmaceuticals
Series A in 2018
Riparian Pharmaceuticals, Inc. is a biotechnology company based in Boston, Massachusetts, focused on discovering innovative therapeutics that address endothelial dysfunction and enhance vascular health. Established in 2012, the company employs advanced models of vascular pathophysiology to develop medical therapies aimed at treating cardiovascular and inflammatory diseases. By targeting new vasoprotective pathways, Riparian Pharmaceuticals seeks to improve endothelial function and reduce vascular complications associated with both common and rare vascular diseases. This approach is designed to enable healthcare providers to achieve better outcomes for their patients.
Clues Therapeutics
Seed Round in 2018
Integrate multi-technology target screening and drug discovery to improve innovation development efficiency.
Dorian Therapeutics
Seed Round in 2018
Dorian Therapeutics is a biotechnology company focused on developing innovative treatments for age-related diseases, including diabetes, Alzheimer's, arthritis, sarcopenia, osteoarthritis, and osteoporosis. The company specializes in rejuvenating cells and tissues through its novel therapeutics, which aim to inhibit the aging process of cells, particularly T cells. By enhancing the function, fitness, and persistence of these immune cells, Dorian Therapeutics enables medical practitioners to reactivate biological processes associated with youthfulness and regeneration. Additionally, the company offers cellular and immunotherapy services to further support therapeutic advancements in combating age-associated conditions.
VersaPeutics
Venture Round in 2018
VersaPeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2017. The company is dedicated to developing innovative treatments for disorders of the nervous system, specifically targeting conditions such as spinal cord injury, traumatic brain injury, and stroke. VersaPeutics aims to achieve breakthroughs in neurosciences to enhance diagnosis and treatment options for these complex medical challenges. The company is in the process of assembling a team of skilled scientists and business professionals to further its mission in the biopharmaceutical landscape.
VivaVision Biotech
Series B in 2018
VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.
Arthrosi Therapeutics
Series A in 2017
Arthrosi Therapeutics is a biotechnology company dedicated to drug discovery and development, with a specific focus on therapies for gout and chronic kidney disease. The company is engaged in clinical-stage research aimed at reducing flare-ups and tophi in gout patients. By developing innovative treatments, Arthrosi Therapeutics enables healthcare professionals to achieve significant uric acid reduction and address joint damage associated with tophi, thereby improving patient outcomes in these conditions.
Dogma Therapeutics
Series A in 2017
Dogma Therapeutics is a biotechnology company based in the United States that specializes in developing small molecule inhibitors targeting PCSK9, a protein involved in cholesterol regulation. The firm has successfully identified orally bioavailable small molecule inhibitors that effectively lower blood lipid levels, addressing a significant challenge in the pharmaceutical industry, where previous attempts primarily relied on monoclonal antibodies. Utilizing high-resolution x-ray structures of their compounds bound to PCSK9, Dogma Therapeutics employs structure-based design to achieve high-affinity interactions. This innovative approach aims to transform the treatment landscape for cholesterol management and improve the economic viability of PCSK9-based therapies.
Path Therapeutics
Venture Round in 2017
Path Therapeutics, Inc. is a biotechnology company based in Calgary, Canada, founded in 2013. It specializes in developing a neurometabolic, phenotypic drug discovery platform aimed at identifying novel protein targets for drug development. The platform leverages phenotypic screening technology to analyze repurposed drug libraries, enabling reverse identification of druggable proteins. By focusing on mitochondrial function, Path Therapeutics seeks to uncover new drug targets for central nervous system disorders, including epilepsy, autism, and aging-related conditions. This innovative approach aims to facilitate de novo drug discovery and improve treatment options for various neurological disorders, particularly rare and pediatric epilepsies.
Flash Therapeutics
Series A in 2016
Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.
Epican Technology Hongkong Limited
Series A in 2016
Epigenetic-based Cancer Diagnostics and Prognostics
Tabomedex Biosciences
Series A in 2016
Tabomedex Biosciences, Inc. is a biotechnology company based in Boxford, Massachusetts, established in 2017. The company is dedicated to the research and development of innovative drug therapies for the treatment of type 2 diabetes. Its primary focus is on the development of allosteric MK2 inhibitors, which are designed to enhance insulin sensitivity and provide significant cardiovascular protective effects. By studying the mechanisms of action of MK2, Tabomedex aims to control blood glucose levels through the inhibition of downstream activating enzymes, contributing to improved management of diabetes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.